$71.01
0.27%
Nasdaq, Apr 21, 08:15 pm CET
ISIN
US4523271090
Symbol
ILMN

Illumina Stock price

$71.20
-14.48 16.90% 1M
-72.32 50.39% 6M
-62.43 46.72% YTD
-44.05 38.22% 1Y
-256.02 78.24% 3Y
-237.03 76.90% 5Y
-115.05 61.77% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-2.33 3.17%
ISIN
US4523271090
Symbol
ILMN
Sector
Industry

Key metrics

Market capitalization $11.27b
Enterprise Value $12.67b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 17.87
EV/Sales (TTM) EV/Sales 2.90
P/S ratio (TTM) P/S ratio 2.58
P/B ratio (TTM) P/B ratio 4.77
Revenue growth (TTM) Revenue growth -2.93%
Revenue (TTM) Revenue $4.37b
EBIT (operating result TTM) EBIT $1.18b
Free Cash Flow (TTM) Free Cash Flow $709.00m
Cash position $1.22b
EPS (TTM) EPS $-7.72
P/E forward 18.44
P/S forward 2.63
EV/Sales forward 2.96
Short interest 4.04%
Show more

Is Illumina a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Illumina Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Illumina forecast:

11x Buy
41%
14x Hold
52%
2x Sell
7%

Analyst Opinions

27 Analysts have issued a Illumina forecast:

Buy
41%
Hold
52%
Sell
7%

Financial data from Illumina

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4,372 4,372
3% 3%
100%
- Direct Costs 1,511 1,511
14% 14%
35%
2,861 2,861
4% 4%
65%
- Selling and Administrative Expenses 162 162
85% 85%
4%
- Research and Development Expense 1,170 1,170
13% 13%
27%
1,529 1,529
328% 328%
35%
- Depreciation and Amortization 354 354
18% 18%
8%
EBIT (Operating Income) EBIT 1,175 1,175
1,710% 1,710%
27%
Net Profit -1,222 -1,222
5% 5%
-28%

In millions USD.

Don't miss a Thing! We will send you all news about Illumina directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Illumina Stock News

Neutral
GlobeNewsWire
3 days ago
Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Target validation for genetic targets" report has been added to ResearchAndMarkets.com's offering.
Neutral
PRNewsWire
6 days ago
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption ...
Neutral
PRNewsWire
11 days ago
SAN DIEGO , April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025.  On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, in...
More Illumina News

Company Profile

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Head office United States
CEO Jacob Thaysen
Employees 10,370
Founded 1998
Website www.illumina.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today